Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,390,000.00 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) CEO Lawrence Klein sold 25,000 shares of the business’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $95.60, for a total transaction of $2,390,000.00. Following the transaction, the chief executive officer owned 923,128 shares of the company’s stock, valued at $88,251,036.80. This trade represents a 2.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Lawrence Otto Klein also recently made the following trade(s):

• On Thursday, October 1st, Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $83.62, for a total transaction of $2,090,500.00.
• On Tuesday, September 15th, Lawrence Klein sold 2,452 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $234,680.92.
• On Tuesday, September 1st, Lawrence Klein sold 75,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $101.41 on Thursday. Oruka Therapeutics, Inc. has a 52-week low of $25.23 and a 52-week high of $115.51. The stock has a fifty day moving average of $88.16 and a 200 day moving average of $69.91.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Equities analysts predict that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ORKA. Wedbush restated an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. BTIG Research reaffirmed a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Monday, October 19th. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Piper Sandler reissued an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $133.00.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently added to or reduced their stakes in ORKA. BlackRock Inc. purchased a new stake in Oruka Therapeutics during the second quarter valued at about $474,916,000. Jupiter Topco LLC bought a new position in shares of Oruka Therapeutics during the second quarter valued at about $130,968,000. Bank of America Corp DE bought a new position in shares of Oruka Therapeutics during the second quarter valued at about $33,578,000. Braidwell LP purchased a new position in shares of Oruka Therapeutics in the second quarter worth about $26,473,000. Finally, Atika Capital Management LLC purchased a new position in shares of Oruka Therapeutics in the first quarter worth about $11,277,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.